A5034035919- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Family Support in Illness
- Cancer-related cognitive impairment studies
- Patient-Provider Communication in Healthcare
- Colorectal Cancer Treatments and Studies
- Reproductive tract infections research
- Gastric Cancer Management and Outcomes
- Childhood Cancer Survivors' Quality of Life
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Sexual function and dysfunction studies
- Syphilis Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Cervical Cancer and HPV Research
- DNA Repair Mechanisms
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Reproductive Biology and Fertility
University of Calgary
2004-2024
Canadian Partnership Against Cancer
2017-2022
International Breast Cancer Study Group
2015-2022
Harvard University
2016-2017
Dana-Farber Cancer Institute
2016-2017
Aboriginal Health Council of South Australia
2017
Frontier Science Foundation
2017
St Vincent's Hospital
2016
Corcept Therapeutics (United States)
2016
Boehringer Ingelheim (Canada)
2016
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) SOFT (Suppression Ovarian Function trials investigated endocrine therapies for premenopausal women with hormone receptor-positive cancer, testing exemestane plus ovarian function suppression (OFS), tamoxifen OFS, alone. We examined absolute treatment effect across a continuum risk to individualize decision making human epidermal growth factor receptor 2...
JCO
PURPOSE Cyclophosphamide, epirubicin, and fluorouracil (CEF) doxorubicin cyclophosphamide (AC) followed by paclitaxel (T) are commonly used adjuvant regimens in women with early breast cancer. In a previous trial locally advanced cancer, 3 months of high-dose epirubicin (EC) administered every 2 weeks (dose-dense) was equivalent to 6 CEF. We hypothesized that after dose-dense EC (EC/T) would be superior CEF or AC/T. METHODS After lumpectomy mastectomy, 60 years age younger axillary...
PURPOSE The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)–positive breast cancer treated adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen OFS versus alone. We previously reported the magnitude absolute improvements in freedom from any recurrence across a continuous, composite measure risk to tailor decision making. With longer follow-up, we now focus on distant...
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled the Suppression Ovarian Function Trial (SOFT) Tamoxifen Exemestane (TEXT). Methods In SOFT, still premenopausal after surgery or without chemotherapy were randomly assigned to tamoxifen alone, plus ovarian function suppression (OFS), exemestane OFS. TEXT, all received OFS concomitant We summarize treatment efficacy, quality life, adherence cohort...
ObjectivesIn 2003 the International Breast Cancer Study Group (IBCSG) initiated TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is role of aromatase inhibitors (AI) treated ovarian function suppression (OFS)? 2-What OFS who remain are tamoxifen?MethodsTEXT patients receive exemestane or tamoxifen OFS. OFS, alone. Treatment was 5 years from randomization.ResultsTEXT...
BackgroundRecent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it uncertain whether to select concurrent or sequential OFS initiation.Design and methodsWe analyzed 1872 enrolled in the randomized phase III TEXT SOFT trials who received for hormone receptor-positive, HER2-negative upon randomization an OFS-containing therapy, initiated...
JCO
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and vivo. A phase II trial combining DPPE doxorubicin (DOX) metastatic breast carcinoma showed increased response over expected with DOX. We report III comparing DOX plus or recurrent cancer.Anthracycline-naive women measurable disease were randomly assigned to receive, every 21 days, either 60 mg/m(2) intravenously during the last 20 minutes of an 80-minute...
Abstract Background: Facilitating healthy levels of physical activity (PA) during chemotherapy is important for the psychosocial and health breast cancer survivors. The primary objective this feasibility study was to examine effects a broad-reach PA behavior change intervention among women with receiving adjuvant chemotherapy. Methods: Breast patients (N = 95) were randomly assigned receive resource kit consisting tailored print materials step pedometer (intervention) or standard public...
Survivorship care plans (scps) have been recommended as a way to ease the transition from active cancer treatment follow-up care, reduce uncertainty for survivors in management of their ongoing health, and improve continuity care. The objective demonstration project reported here was assess value scps western Canada.The Alberta CancerBridges team developed, implemented, evaluated 36 breast 21 head-and-neck survivors. For evaluation, we interviewed 12 survivors, 9 nurses who delivered scps, 3...
Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response side effects, mainly postmenopausal women early cancer. This analysis aimed to assess association of selected germline CYP19A1 ESR1 SNPs early-onset hot flashes, sweating musculoskeletal symptoms premenopausal patients enrolled Tamoxifen Exemestane Trial (TEXT). Blood was collected from consenting...
LBA1 Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC. TEXT and SOFT were designed to test whether adjuvant premenopausal women BC treated OFS (AI question) determine the value of who remain are suitable for (OFS question). Methods: SOFT, randomized phase 3 trials, enrolled 5,738 early from Nov03 Apr11 (2672 TEXT; 3066 SOFT). within 12wk surgery 5y E+OFS T+OFS; chemotherapy (CT) was optional concurrent OFS. T+OFS alone, either if no CT planned,...
503 Background: The TEXT and SOFT trials randomly assigned premenopausal women with HR+ BC to exemestane plus ovarian function suppression (E+OFS), tamoxifen+OFS (T+OFS) T alone. We previously examined absolute treatment effects on any recurrence across a continuum of risk individualize endocrine therapy decision making. After 8.5 yrs median follow-up we now consider freedom from distant recurrence. Methods: HR+/HER2- analysis population included 4891 pts was stratified by chemotherapy use....
557 Background: Little is known about endocrine symptoms, QoL and sexual function in premenopausal women with BC receiving adjuvant therapy. TEXT SOFT are the first trials providing patient-reported data this population. Methods: From Nov 2003 to Apr 2011, 4096 patients (pts) HR+ were enrolled included analysis of randomized phase III trials, SOFT, receive treatment 5 yrs E+OFS or T+OFS. Chemotherapy (chemo) was optional both trials; received concurrently OFS after randomization prior...
Abstract Background The updated combined SOFT+TEXT analysis, after 9 years median follow-up (MFU), revealed that adjuvant E+OFS vs T+OFS significantly improved disease-free survival (DFS) and distant recurrence-free interval (DRFI) but not overall (OS) in premenopausal women with HR+ early BC (Francis et al NEJM 2018). Given the high rate of OS both arms long-term risk relapse BC, continued is key to assessing treatment benefit. We report a planned update analysis including database lock May...
Data from BIG1-98 along with pre-clinical findings point to a partial resistance tamoxifen (T) among postmenopausal women diagnosed ILC. The TEXT and SOFT trials assigned premenopausal hormone receptor-positive (ER+) tumors exemestane plus ovarian function suppression (E+OFS) or T + OFS, alone in only. This analysis includes centrally reviewed ER+HER2-negative (n=4115) classified as invasive ductal carcinoma (IDC), (n=3370) ILC (n=345). Cox model analyses stratified by trial chemotherapy use...